Can you just stop taking Mounjaro — and what actually happens when you do?

What happens in your body when tirzepatide stops

Mounjaro works by activating two gut-hormone receptors (GIP and GLP-1) that together slow gastric emptying, reduce appetite and help regulate blood sugar. That action is present only while the medicine is active in your system. Tirzepatide has a half-life of around five days, which means meaningful concentrations are still circulating for several weeks after the last injection. During that window, some of the effects persist. After that, they do not.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults for 72 weeks and recorded average body-weight reductions of around 20–21% at the 15mg dose. Extension and post-trial data from similar programmes consistently show that when GLP-1 class medicines are stopped without a structured plan, a substantial proportion of that lost weight returns within twelve months. That is not a failing of willpower, it reflects the biology the medicine was managing on your behalf.

Practically, people who stop often notice hunger returning within two to four weeks of their last dose, sometimes accompanied by a return of food preoccupation or cravings that had quietened during treatment. Blood sugar changes in people with type 2 diabetes can appear even sooner. None of this is dangerous in itself, but it underlines why an unplanned stop (say, missing several pens because of a supply issue) is worth a conversation with your prescriber sooner rather than later.

Situations where stopping is the right call, and situations where it may not be

There are clinical circumstances where stopping tirzepatide is the appropriate and sometimes urgent decision. Pregnancy is one: Mounjaro is not recommended during pregnancy or breastfeeding, and women who are trying to conceive should discuss timing with their prescriber well in advance, since a wash-out period is advised. People scheduled for surgery should also inform their anaesthetist and surgical team, and the prescriber may advise pausing treatment in the lead-up to a procedure, because slowed gastric emptying carries anaesthetic risk.

Certain side effects (particularly severe, persistent abdominal pain that radiates to the back, which can signal pancreatitis) require stopping the medicine and seeking urgent medical attention. The MHRA has issued specific guidance on pancreatitis risk with GLP-1 medicines, and that symptom pattern should never be waited out at home.

By contrast, a short break for a holiday abroad does not automatically mean stopping entirely. Whether to pause, carry pens, or adjust is a practical question with a clinical dimension, our page on pausing Mounjaro for a holiday covers this in detail. Similarly, people who have reached their treatment goal and are wondering about long-term use will find the question of when stopping makes clinical sense is a different one from whether stopping is possible.

How to stop if stopping is the right decision

There is no medically mandated taper for tirzepatide the way there is for some other medicines. Stopping at any dose (2.5mg or 15mg) does not require a step-down protocol in most cases. That said, abruptly stopping at a higher dose may produce a more noticeable return of appetite than stepping down would, and some prescribers prefer a gradual reduction for that reason. This is a clinical judgement, not a rule written into the licence.

If stopping is planned, the period immediately after is the one that benefits most from the lifestyle habits built during treatment. Protein adequacy, regular movement and not letting weeks pass without weighing in all matter more during this window than at any other point. The NHS guidance on tirzepatide on the NHS medicines pages covers the practical information in the Patient Information Leaflet; our guide to stopping Mounjaro goes further on the process and what to expect.

For anyone weighing up stopping Mounjaro specifically for weight management, the core question is whether the treatment goal has been met, whether it can be maintained without the medicine, or whether a planned break is part of a longer strategy. Those are not questions with universal answers. Our prescribers hear this question most weeks, usually from people who are doing well and wondering whether they still need the medicine, or from people unsure what happens next. It is exactly the kind of conversation worth having before the last pen goes in the bin.

The cost dimension: if price is behind the question

It is worth naming directly: some people ask whether they can just stop taking Mounjaro because they are looking at the ongoing cost and wondering whether it is sustainable. That is a practical concern and a fair one. Private treatment pricing has shifted considerably since Eli Lilly raised UK list prices in September 2025, and the question of what Mounjaro costs and what drives those figures is one we cover honestly. If cost is the driver, a prescriber is still the right first conversation, there may be NHS eligibility to explore, a dose adjustment that changes the picture, or a structured plan for stepping down that protects the progress already made. Stopping quietly without that conversation is the option that tends to serve people least well.

If you have questions about your treatment or are considering a change, speak to our prescribers, it costs nothing and there is no obligation to do anything different afterwards.